Phase I/II, open labeled, prospective trial to study safety and efficacy of Chidamide Plus DCAG for Relapsed/Refractory Acute myeloid leukaemia (AML).
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Decitabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Tucidinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Feb 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 21 Sep 2016 New trial record